1. Multiple lentigines confined to psoriatic plaques induced by biologic agents in psoriasis therapy: a case and review of the literature;Dogan;Cutan Ocul Toxicol,2015
2. Multiple lentigines in areas of resolving psoriatic plaques after ustekinumab therapy;Gutierrez-Gonzalez;Dermatol Online J,2014
3. Lentigines in resolving psoriatic plaques: rarely reported sequelae in pediatric cases;LaRosa;Pediatr Dermatol,2015
4. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2);Paul;Br J Dermatol,2015
5. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1);Papp;J Am Acad Dermatol,2015